NGS-Based RNA-Sequencing Market By Technology (Sequencing by Synthesis, Nanopore Sequencing, Others); By Application (Transcriptome Profiling, Differential Gene Expression Analysis, Fusion Gene Detection, Small RNA Sequencing, Others); By End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Clinical Laboratories, Contract Research Organizations); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global NGS -Based RNA -Sequencing Market will witness a robust CAGR of 15.7% , valued at USD 4.85 billion in 2024 , expected to appreciate and reach USD 11.63 billion by 2030 , confirms Strategic Market Research.

 

Next-Generation Sequencing (NGS)-based RNA-sequencing has fundamentally transformed genomic analysis by enabling comprehensive transcriptome profiling, quantification of gene expression, and discovery of novel transcripts, splice variants, and gene fusions with exceptional accuracy and throughput. As of 2024 , the technology holds critical strategic relevance in numerous sectors, including oncology research, personalized medicine, infectious disease monitoring, and drug development pipelines.

 

Several macro-level drivers underpin the market’s trajectory:

• Technological Advancements: Ongoing innovation in sequencing chemistries, library preparation protocols, and bioinformatics tools has significantly reduced costs while improving data quality and speed, expanding RNA- seq applications into routine clinical and translational research settings.

• Rising Disease Burden: The escalating incidence of cancer, rare genetic diseases, and emerging infectious pathogens demands deeper molecular insights, driving reliance on RNA- seq for disease diagnostics, therapeutic targeting, and biomarker development.

• Precision Medicine Initiatives: National healthcare systems and private entities continue investing heavily in genomic infrastructure to enable precision medicine. RNA- seq is central to stratifying patients, predicting drug response, and guiding targeted therapies.

• Regulatory Encouragement: Regulatory agencies are increasingly recognizing molecular diagnostics, including RNA- seq -based assays, as essential components of drug approval processes and companion diagnostics, creating favorable conditions for market growth.

In addition to these drivers, RNA- seq is gaining traction in agricultural genomics, immunology, neuroscience, and single-cell transcriptomics , broadening its commercial potential beyond purely medical applications.

 

Key stakeholders shaping this market include:

• Original Equipment Manufacturers (OEMs): Developing innovative NGS platforms and library prep kits

• Bioinformatics Companies: Providing advanced analysis pipelines, AI tools, and cloud-based platforms for RNA- seq data interpretation

• Healthcare Providers and Research Institutions: Leveraging RNA- seq for clinical and translational research

• Pharmaceutical and Biotech Companies: Integrating RNA- seq into drug discovery, biomarker development, and clinical trials

• Government Bodies and Funding Agencies: Supporting genomics infrastructure and large-scale sequencing projects

• Investors and Venture Capital Firms: Funding emerging RNA- seq technology developers and start-ups

Experts anticipate that as sequencing costs continue to fall, RNA- seq will shift further into clinical diagnostics, revolutionizing how diseases are classified, monitored, and treated. The convergence of NGS technology with artificial intelligence and machine learning promises transformative gains in both speed and interpretability of RNA data, paving the way for highly personalized patient care.

The NGS-based RNA-sequencing market thus represents a rapidly growing segment of the broader genomics and precision medicine ecosystem, poised for significant expansion through 2030 .

 

Market Segmentation And Forecast Scope

The NGS-based RNA-sequencing market can be systematically segmented to capture the diverse technologies, applications, end-user environments, and geographic dynamics driving growth between 2024 and 2030 . The following segmentation framework reflects the industry’s operational and commercial landscape.

By Technology

• Sequencing by Synthesis (SBS ) The dominant method, widely used due to high accuracy, scalability, and cost-effectiveness. SBS underpins platforms from major manufacturers and is crucial for bulk and single-cell transcriptomics .

• Nanopore Sequencing An emerging approach allowing long-read RNA sequencing in real-time. Nanopore technologies are gaining traction for detecting isoforms, RNA modifications, and full-length transcripts.

• Other Technologies Including SMRT sequencing, pyrosequencing, and hybrid techniques designed to enhance read length, sensitivity, or specific transcript coverage.

As of 2024, Sequencing by Synthesis (SBS) accounts for approximately 68% of total revenue, owing to its entrenched clinical and research adoption.

 

By Application

• Transcriptome Profiling Covers gene expression analysis, alternative splicing detection, and RNA editing studies across bulk and single-cell platforms.

• Differential Gene Expression Analysis Enables researchers to compare disease vs. healthy states, or treated vs. untreated groups, vital in oncology and drug development.

• Fusion Gene Detection Increasingly crucial in cancer diagnostics and therapeutics, RNA- seq enables identification of oncogenic gene fusions.

• Small RNA Sequencing Involves profiling of miRNA, siRNA, and other non-coding RNAs implicated in gene regulation and disease pathways.

• Others Including isoform discovery, single-cell RNA- seq , and spatial transcriptomics .

Among applications, Transcriptome Profiling remains the cornerstone segment and is anticipated to maintain the largest share through 2030 , driven by its pivotal role in research and precision medicine.

 

By End User

• Academic and Research Institutes The largest consumers of RNA- seq services and technology for fundamental biological research and large-scale consortium projects.

• Pharmaceutical and Biotechnology Companies Integrate RNA- seq into drug discovery, target validation, and biomarker development workflows.

• Hospitals and Clinical Laboratories Rapidly growing adopters of RNA- seq for diagnostic and prognostic applications, especially in oncology and rare diseases.

• Contract Research Organizations (CROs ) Offering RNA- seq as part of genomic services for biopharma clients.

While Academic and Research Institutes lead the market in revenue terms, the Hospitals and Clinical Laboratories segment is expected to register the fastest CAGR, reflecting RNA- seq’s transition from research to clinical practice.

 

By Region

• North America Dominates the global market, driven by advanced research infrastructure, significant funding, and early clinical adoption.

• Europe Benefits from collaborative genomic initiatives, growing clinical applications, and strong regulatory support.

• Asia-Pacific Exhibiting the fastest growth, fueled by government genomic programs, booming biotech sectors, and cost-effective NGS services.

• Latin America, Middle East, and Africa (LAMEA ) An emerging market with rising research investments and improved healthcare infrastructure.

In 2024, North America captures over 42% of market revenue; however, Asia-Pacific is projected to expand at the highest CAGR through 2030 .

Industry experts predict that as single-cell RNA sequencing and spatial transcriptomics gain momentum, new sub-segments will emerge, reshaping revenue distribution across applications and technologies.

This segmentation ensures comprehensive coverage of growth opportunities, guiding stakeholders in investment and strategic planning for the NGS-based RNA-sequencing market .

 

Market Trends And Innovation Landscape

The NGS-based RNA-sequencing market is undergoing rapid transformation, driven by breakthroughs in technology, computational tools, and evolving scientific applications. Several key trends define the innovation landscape between 2024 and 2030 .

Surge in Single-Cell and Spatial Transcriptomics

One of the most transformative trends in the RNA- seq field is the shift from bulk transcriptomics to single-cell RNA sequencing ( scRNA-seq ) and spatial transcriptomics . These technologies enable researchers to capture gene expression at an unprecedented resolution, revealing cellular heterogeneity in tissues and tumor microenvironments.

Experts highlight that single-cell RNA- seq is crucial for understanding cancer evolution, immune cell dynamics, and developmental biology, paving the way for novel therapeutic interventions.

Companies are launching integrated solutions that combine spatial context with transcriptomic data, fueling demand among academic institutes and biotech firms.

 

Advancements in Long-Read RNA Sequencing

Long-read sequencing technologies —notably nanopore and SMRT sequencing—are rapidly improving in accuracy and affordability. Long-read RNA- seq is essential for detecting full-length transcripts, alternative splicing events, and isoform diversity that are difficult to resolve using short-read methods.

This is particularly impactful for identifying disease-specific transcript isoforms and fusion events in oncology and rare disease research.

Several players are developing hybrid sequencing approaches that integrate long- and short-read data for a more comprehensive transcriptome view.

 

AI and Machine Learning in Transcriptomic Data Analysis

Massive data output from RNA- seq experiments has created a pressing need for sophisticated analytics. Artificial intelligence (AI) and machine learning (ML) algorithms are increasingly deployed to:

• Predict novel gene functions

• Identify disease-associated gene expression patterns

• Optimize sequencing workflows

• Accelerate data interpretation for clinical reporting

Industry insiders note that AI-driven tools are reducing turnaround times for RNA- seq data analysis from weeks to hours, democratizing access for non-bioinformatics users.

Cloud-based bioinformatics platforms are also expanding, enabling scalable and collaborative data processing without the burden of local infrastructure.

 

Emergence of RNA Modifications ( Epitranscriptomics )

Researchers are exploring the epitranscriptome —chemical modifications on RNA molecules that regulate stability, translation, and function. Technologies capable of detecting such modifications via direct RNA sequencing are emerging as a significant innovation frontier.

This niche is anticipated to spark new diagnostic and therapeutic targets, especially in cancer, neurodegenerative diseases, and viral infections.

 

Strategic Partnerships and M&A Activity

The market has seen active collaboration between:

• NGS platform manufacturers and bioinformatics providers

• Pharma companies and sequencing service providers for biomarker discovery

• Tool developers specializing in single-cell analysis and spatial technologies

These partnerships aim to deliver end-to-end solutions covering sample prep, sequencing, data analysis, and clinical reporting.

Recent examples include:

• Collaborations focused on developing clinical-grade RNA- seq assays for oncology diagnostics

• M&A deals where established NGS vendors acquire emerging bioinformatics firms to integrate analytics capabilities into their portfolios

Industry voices emphasize that consolidation and alliances are critical for translating RNA- seq technologies into clinical practice efficiently and cost-effectively.

 

Cost Reduction and Workflow Simplification

Although sequencing costs have decreased dramatically over the past decade, RNA- seq still involves complex library preparation and data analysis workflows. Vendors are heavily investing in:

• Automation of library preparation

• Low-input and rapid protocols

• Cost-efficient reagent kits

• All-in-one informatics solutions

As workflows become simpler and more affordable, adoption of RNA- seq is anticipated to expand significantly in routine clinical diagnostics, especially in oncology.

The NGS-based RNA-sequencing market stands at the intersection of technological innovation and expanding biomedical applications. The coming years will witness even deeper integration of RNA- seq into clinical decision-making, drug development pipelines, and personalized medicine, setting the stage for accelerated market growth through 2030 .

 

Competitive Intelligence And Benchmarking

The NGS-based RNA-sequencing market is highly competitive and technologically dynamic, with numerous players ranging from established sequencing giants to emerging innovators. Competition hinges on platform performance, breadth of applications, bioinformatics integration, and strategic partnerships.

Below is a profile of 7 major companies shaping this market landscape:

Illumina

• Strategy: Maintains market leadership through continuous innovation in Sequencing by Synthesis (SBS) platforms, with a strong focus on lowering sequencing costs and expanding into clinical markets.

• Global Reach: Operates extensively worldwide, serving academic, clinical, and commercial clients.

• Product Differentiation: Offers high-throughput platforms and comprehensive informatics tools, making it the dominant supplier for bulk RNA- seq and emerging single-cell applications.

• Illumina is increasingly targeting regulated markets, aiming for clinical-grade RNA- seq assays for cancer diagnostics and genetic diseases.

 

Thermo Fisher Scientific

• Strategy: Focuses on integrated workflows, combining sequencing instruments, reagents, and bioinformatics. Strong in targeted RNA- seq panels for clinical applications.

• Global Reach: Operates across major continents with strong distribution networks and a diversified portfolio.

• Product Differentiation: Emphasizes ease-of-use systems suitable for translational research and diagnostics, especially in oncology and infectious diseases.

• Thermo Fisher’s strategic acquisitions have reinforced its presence in clinical genomics and molecular diagnostics.

 

Pacific Biosciences ( PacBio )

• Strategy: Specializes in long-read sequencing to capture full-length transcripts and complex isoforms, a niche crucial for advanced transcriptomics .

• Global Reach: Gaining traction in North America, Europe, and Asia-Pacific, especially among research institutions and large-scale projects.

• Product Differentiation: Provides highly accurate long reads, enabling precise isoform characterization and novel transcript discovery.

• PacBio’s technology is increasingly adopted for understanding alternative splicing and epitranscriptomic modifications, enhancing its role in RNA- seq innovation.

 

Oxford Nanopore Technologies

• Strategy: Focuses on portable, real-time, long-read sequencing devices, disrupting traditional sequencing workflows.

• Global Reach: Rapidly expanding presence in Europe, Asia, and North America.

• Product Differentiation: Unique ability to directly sequence native RNA molecules, preserving RNA modifications and delivering ultra-long reads.

• Oxford Nanopore’s platforms are particularly attractive for field-based research, infectious disease surveillance, and emerging epitranscriptomics studies.

 

BGI Genomics

• Strategy: Leverages high-throughput sequencing capacity to offer competitive pricing for RNA- seq services globally. Also develops proprietary NGS platforms.

• Global Reach: Strong in Asia-Pacific, expanding into Europe and North America.

• Product Differentiation: Combines sequencing services with proprietary bioinformatics pipelines and extensive experience in large-scale genomic projects.

• BGI plays a key role in population-scale transcriptomics initiatives and collaborative genomics research worldwide.

 

Agilent Technologies

• Strategy: Focuses on RNA library preparation kits, target enrichment solutions, and automation tools for streamlined RNA- seq workflows.

• Global Reach: Well-established globally, with customers in research, pharma, and clinical labs.

• Product Differentiation: Known for high-quality reagents and hybrid capture technologies critical for targeted RNA- seq applications.

• Agilent’s innovations help reduce input requirements and turnaround times, driving adoption in both research and clinical contexts.

 

10x Genomics

• Strategy: Pioneers single-cell and spatial transcriptomics technologies, enabling high-resolution gene expression analysis.

• Global Reach: Rapidly expanding footprint among top-tier research institutes worldwide.

• Product Differentiation: Offers end-to-end solutions for single-cell RNA- seq , spatial gene expression mapping, and multi-omics integration.

• 10x Genomics is transforming how scientists explore cellular heterogeneity, playing a pivotal role in drug discovery and disease characterization.

Industry observers note that partnerships between sequencing instrument manufacturers and bioinformatics firms are increasingly critical, as customers demand seamless solutions from sample to insight. Emerging players focusing on AI-powered RNA- seq analytics are also poised to disrupt established workflows.

Overall, the competitive landscape remains vibrant, with companies racing to innovate in areas such as long-read sequencing, single-cell analysis, cost reduction, and clinical-grade applications. This dynamism ensures rapid market evolution through 2030 .

 

Regional Landscape And Adoption Outlook

Regional dynamics significantly shape the growth trajectory of the NGS-based RNA-sequencing market , driven by disparities in research funding, technological infrastructure, healthcare systems, and regulatory environments. Between 2024 and 2030 , adoption patterns will vary considerably across major geographies.

North America

• Market Position: Dominates the global market, accounting for over 42% of revenue in 2024 .

Key Drivers:

• Substantial government and private funding for genomics research (e.g., NIH initiatives)

• Early adoption of NGS technologies in clinical diagnostics, especially oncology

• Robust biotech and pharma ecosystems integrating RNA- seq in drug development

Adoption Trends:

• Rapid uptake of single-cell RNA- seq and spatial transcriptomics

• Growing demand for RNA- seq as a clinical diagnostic tool, supported by evolving FDA guidelines

Country Highlights:

• United States: Global leader in research output, major RNA- seq technology development hub

• Canada: Rising investments in precision medicine and national genomics strategies

Experts suggest North America’s continued dominance is underpinned by translational research efforts and commercialization of RNA- seq for routine diagnostics.

 

Europe

• Market Position: Second-largest market, with steady growth driven by collaborative genomics programs.

Key Drivers:

• EU-backed projects like the European 1+ Million Genomes Initiative

• Focus on regulatory harmonization for molecular diagnostics

• Strong academic infrastructure and clinical research

Adoption Trends:

• Increasing applications in rare disease research and oncology

• Expansion of RNA- seq into agricultural and environmental genomics

Country Highlights:

• Germany: Major hub for genomic services and biotech innovation

• United Kingdom: Active in clinical genomics and NHS-integrated sequencing efforts

• France, Italy, Spain: Participating in pan-European genomics collaborations

European markets are emphasizing regulatory clarity and public-private partnerships to integrate RNA- seq into national healthcare systems.

 

Asia-Pacific

• Market Position: Fastest-growing region, poised for significant market share gains by 2030 .

Key Drivers:

• Massive government investments in national genomic medicine programs (e.g., China’s Precision Medicine Initiative)

• Growing demand for affordable NGS services

• Expansion of domestic sequencing platforms competing with Western technologies

Adoption Trends:

• Increasing clinical use of RNA- seq for oncology and infectious disease monitoring

• Surging interest in single-cell and spatial transcriptomics among top-tier research institutions

Country Highlights:

• China: Dominant regional player, leading large-scale population genomics projects and fostering local RNA- seq innovators

• Japan: Advanced genomics research community, integrating RNA- seq into cancer diagnostics

• India: Emerging hub for cost-effective sequencing services and clinical trials

Industry analysts predict Asia-Pacific will contribute disproportionately to RNA- seq volume growth, given its massive patient pools and favorable cost structures.

 

Latin America, Middle East, and Africa (LAMEA)

• Market Position: Represents a smaller portion of global revenue but with high future potential.

Key Drivers:

• Gradual improvements in research infrastructure

• Increasing government and private investments in genomic medicine

• Growing awareness of precision medicine benefits

Adoption Trends:

• Latin America adopting RNA- seq for oncology and agricultural genomics

• Middle East investing in genomic initiatives to diversify economies and healthcare systems

• Africa seeing early-stage efforts in genomic surveillance for infectious diseases

Country Highlights:

• Brazil: Leading regional adopter with expanding genomic services market

• Saudi Arabia, UAE: Funding national precision medicine and genome sequencing projects

• South Africa: Building capacity for genomic surveillance and personalized medicine

Though currently underserved, LAMEA holds significant long-term potential as healthcare systems modernize and genomic technologies become more accessible.

 

White Space and Underserved Regions

• Sub-Saharan Africa: Limited infrastructure for NGS remains a barrier, but initiatives around infectious disease surveillance and maternal health genomics could create future opportunities.

• Latin America (outside Brazil): Cost and regulatory barriers persist, slowing widespread adoption.

Industry observers emphasize that closing these regional gaps will require partnerships, technology transfer, and cost-effective service models.

The regional outlook confirms that while North America and Europe will remain pivotal markets, the Asia-Pacific region is poised to lead in growth, driven by both scale and strategic investments. Emerging regions represent untapped opportunities for market expansion, particularly as RNA- seq migrates into clinical applications globally.

 

End-User Dynamics And Use Case

The adoption of NGS-based RNA-sequencing varies significantly across end-user segments, reflecting differences in research focus, budgets, regulatory requirements, and clinical needs. Understanding these dynamics is essential for stakeholders aiming to capture opportunities in this rapidly evolving market.

Academic and Research Institutes

• Role: Largest consumer segment, driven by basic science research, disease biology studies, and large-scale transcriptomic projects.

Key Drivers:

• Government grants and consortium funding

• Need for high-resolution transcriptomics for publications and discoveries

Usage Patterns:

• Bulk RNA- seq remains a staple for gene expression profiling

• Rapid expansion into single-cell and spatial transcriptomics

• Researchers emphasize RNA- seq’s unparalleled ability to unravel complex biological systems, fueling discoveries in immunology, neuroscience, and developmental biology.

 

Pharmaceutical and Biotechnology Companies

• Role: Integral users of RNA- seq in drug discovery, target validation, and biomarker development.

Key Drivers:

• Demand for companion diagnostics

• Integration into preclinical and clinical trial pipelines

Usage Patterns:

• Identification of gene fusions and novel transcripts relevant to targeted therapies

• Monitoring treatment response through transcriptomic biomarkers

• Pharma companies increasingly rely on RNA- seq to optimize patient stratification in clinical trials, improving drug development success rates.

 

Hospitals and Clinical Laboratories

• Role: Fastest-growing segment as RNA- seq transitions into clinical diagnostics.

Key Drivers:

• Precision medicine initiatives

• Need for comprehensive cancer profiling

Usage Patterns:

• Routine use of RNA- seq panels in hematologic and solid tumor diagnostics

• Application in rare disease diagnosis where gene panels are insufficient

• Hospital labs highlight RNA- seq’s value in detecting gene fusions and alternative splicing events critical for therapy decisions, particularly in oncology.

 

Contract Research Organizations (CROs)

• Role: Providers of specialized RNA- seq services for pharma, biotech, and academic clients.

Key Drivers:

• Outsourcing trend in drug development

• Need for specialized bioinformatics expertise

Usage Patterns:

• Offering turnkey solutions from sample prep to data interpretation

• Supporting multi- omic studies integrating RNA- seq with other datasets

• CROs play a crucial role in democratizing access to advanced RNA- seq technologies for smaller biotech firms and research groups.

 

Real-World Use Case

Here’s a realistic example illustrating the impact of RNA- seq in a clinical setting:

A leading tertiary hospital in South Korea implemented NGS-based RNA-sequencing to enhance lung cancer diagnostics. Traditionally reliant on DNA panels, the hospital integrated an RNA- seq assay into its workflow to detect gene fusions such as ALK, ROS1, and RET, which are critical for targeted therapy selection. In a cohort of 300 lung cancer patients, the RNA- seq assay identified actionable fusions in 12% of cases that were missed by DNA-only testing. This led to a direct change in treatment plans, enabling these patients to access targeted therapies, ultimately improving progression-free survival outcomes. The hospital has since standardized RNA- seq as part of its lung cancer diagnostic protocol, reducing turnaround time for molecular results from 21 days to 10 days.

Experts underline that such integration of RNA- seq into routine diagnostics not only improves patient outcomes but also enhances operational efficiency in healthcare institutions.

 

Key End-User Trend : Across all segments, there is growing emphasis on simplified workflows, faster turnaround times, and user-friendly bioinformatics platforms to support adoption beyond highly specialized labs.

The diverse end-user base underscores why the NGS-based RNA-sequencing market remains one of the most dynamic spaces in the life sciences industry, with transformative implications for research, diagnostics, and therapeutic development through 2030 .

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

The NGS-based RNA-sequencing market has witnessed significant activity from technology launches to strategic collaborations, reinforcing its trajectory toward clinical and advanced research applications.

1. PacBio Unveils Revio Long-Read Sequencer

In 2024, Pacific Biosciences launched the Revio system, a high-throughput long-read sequencer designed to dramatically lower costs per gigabase . This system enables more cost-effective full-length RNA sequencing, crucial for isoform detection and transcriptome completeness.

 

2. Illumina Partners with Myriad Genetics for RNA-based Oncology Panels

Illumina announced a collaboration with Myriad Genetics in 2023 to develop RNA-based assays targeting fusion genes in solid tumors, supporting comprehensive molecular profiling for cancer patients.

 

3. 10x Genomics Expands Spatial Transcriptomics Portfolio

In 2023, 10x Genomics released updated solutions for spatial transcriptomics , allowing simultaneous mapping of gene expression and tissue morphology at single-cell resolution—a significant advance for cancer research and developmental biology.

 

4. Oxford Nanopore Advances Direct RNA Sequencing

Oxford Nanopore Technologies has improved direct RNA sequencing protocols, increasing read accuracy for detecting RNA modifications, a critical step for expanding epitranscriptomics research.

 

5. Thermo Fisher Introduces Oncomine RNA Panels for Liquid Biopsy

In late 2023, Thermo Fisher Scientific launched new RNA-based panels tailored for liquid biopsy applications, enabling detection of gene fusions and expression profiles from circulating tumor RNA.

 

Opportunities

1. Clinical Diagnostics Adoption

The migration of RNA- seq into clinical practice, particularly in oncology, offers vast market potential. As reimbursement frameworks evolve and assay costs decline, hospitals and diagnostic labs are increasingly integrating RNA- seq for:

• Fusion gene detection

• Drug resistance profiling

• Treatment selection

This transition could significantly expand the addressable market beyond research.

2. AI-Driven Bioinformatics

AI and machine learning tools for RNA- seq analysis are simplifying data interpretation, reducing turnaround times, and enabling non-specialists to utilize complex transcriptomic insights.

Vendors investing in user-friendly analytics solutions are likely to gain substantial competitive advantage.

3. Growth in Emerging Regions

Countries across Asia-Pacific, the Middle East, and Latin America are investing in genomic infrastructure and precision medicine, creating new markets for affordable RNA- seq services.

Lower-cost solutions tailored for these regions will unlock significant untapped demand.

 

Restraints

1. High Cost of Sequencing and Data Analysis

Despite declining prices, RNA- seq remains cost-prohibitive for routine use in some settings, especially in emerging economies. Costs include:

• Library preparation

• Sequencing runs

• Advanced bioinformatics analysis

This limits broader clinical adoption and delays routine diagnostic integration.

 

2. Bioinformatics Complexity and Data Storage Challenges

Interpreting RNA- seq data demands specialized expertise and significant computational resources. Many institutions lack the infrastructure or skilled personnel required for large-scale projects.

These technical barriers can delay projects and limit adoption among smaller labs and hospitals.

The balance between innovation and cost-effectiveness will determine how quickly RNA- seq transitions from research into widespread clinical use. However, the market remains highly attractive, with vast opportunities across diagnostic and therapeutic landscapes through 2030 .

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 4.85 Billion
Revenue Forecast in 2030	USD 11.63 Billion
Overall Growth Rate	CAGR of 15.7% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Technology, By Application, By End User, By Geography
By Technology	Sequencing by Synthesis, Nanopore Sequencing, Others
By Application	Transcriptome Profiling, Differential Gene Expression Analysis, Fusion Gene Detection, Small RNA Sequencing, Others
By End User	Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Clinical Laboratories, Contract Research Organizations
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, etc.
Market Drivers	- Adoption of RNA-seq in clinical diagnostics - Advances in single-cell and spatial transcriptomics - AI-driven bioinformatics solutions
Customization Option	Available upon request